Track topics on Twitter Track topics that are important to you
RATIONALE: RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- To assess the antitumor activity of gamma-secretase inhibitor RO4929097 in patients with advanced, metastatic, and/or recurrent triple-negative breast cancer through the co-primary endpoints of overall response rate using RECIST and 6-month progression-free survival (PFS).
- To assess the antitumor activity of gamma-secretase inhibitor RO4929097 through secondary endpoints, including duration of radiologic response, PFS rate, and overall survival rate.
- To assess the safety and tolerability of gamma-secretase inhibitor RO4929097 in patients with breast cancer.
- To explore the expression of Notch biomarkers in triple-negative breast cancer and potential interaction with gamma-secretase inhibitor RO4929097 response and toxicity. (exploratory)
- To evaluate the downstream effects of gamma-secretase inhibitor RO4929097 in patients with advanced triple-negative breast cancer. (exploratory)
OUTLINE: This is a multicenter study.
Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Patients undergo biopsy at baseline and at 4-5 weeks and blood samples are collected periodically for correlative laboratory studies.
After completion of study treatment, patients are followed up monthly for 12 months and then every 3 months thereafter.
Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment
gamma-secretase inhibitor RO4929097, laboratory biomarker analysis
Tom Baker Cancer Centre - Calgary
National Cancer Institute (NCI)
Published on BioPortfolio: 2014-08-27T03:12:37-0400
RATIONALE: Enzyme inhibitors, such as gamma-secretase inhibitor RO4929097, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I...
RATIONALE: Gamma-secretase inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hy...
RATIONALE: Gamma-secretase inhibitor RO4929097 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II clinical trial is study...
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and...
RATIONALE: Gamma-secretase inhibitor RO4929097 and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate also may s...
How to effectively delivering therapeutic agents, including γ-secretase inhibitors (GSIs), into live cells, remains a significant challenge. This study assessed the effect of Notch signaling inhibiti...
The clinical assessment of circulating tumor cells (CTCs) as a blood-based biomarker is FDA-approved for use in breast, colorectal, and prostate cancers. The objective of this prospective clinical stu...
The aim of this study was to evaluate the clinical efficacy of APC gene promoter methylation in serum as a biomarker for breast cancer (BC) diagnosis.
Breast cancer (BC) is the second leading cause of cancer-related mortality in women. Bioinformatic analysis and expression screening showed that Prolactin Induced Protein (PIP) was differentially expr...
The Notch pathway is frequently activated in cancer. Pathway inhibition by γ-secretase inhibitors has been shown to be effective in pre-clinical models of pancreatic cancer, in combination with gemci...
A fluid-filled closed cavity or sac that is lined by an EPITHELIUM and found in the BREAST. It may appear as a single large cyst in one breast, multifocal, or bilateral in FIBROCYSTIC BREAST DISEASE.
Integral membrane protein of Golgi and endoplasmic reticulum. Its homodimer is an essential component of the gamma-secretase complex that catalyzes the cleavage of membrane proteins such as NOTCH RECEPTORS and AMYLOID BETA-PROTEIN precursors. PSEN2 mutations cause ALZHEIMER DISEASE type 4.
Integral membrane proteins and essential components of the gamma-secretase complex that catalyzes the cleavage of membrane proteins such as NOTCH RECEPTORS and AMYLOID BETA-PROTEIN precursors. Mutations of presenilins lead to presenile ALZHEIMER DISEASE with onset before age 65 years.
An analogue of GAMMA-AMINOBUTYRIC ACID. It is an irreversible inhibitor of 4-AMINOBUTYRATE TRANSAMINASE, the enzyme responsible for the catabolism of GAMMA-AMINOBUTYRIC ACID. (From Martindale The Extra Pharmacopoeia, 31st ed)
Endopeptidases that are specific for AMYLOID PROTEIN PRECURSOR. Three secretase subtypes referred to as alpha, beta, and gamma have been identified based upon the region of amyloid protein precursor they cleave.
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Track and monitor developments in breast cancer research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...